Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
$EOLS
Sector
Primary listing
Employees
394
Headquarters
Website
Evolus Metrics
BasicAdvanced
$467M
-
-$0.97
1.07
-
Price and volume
Market cap
$467M
Beta
1.07
52-week high
$17.12
52-week low
$5.71
Average daily volume
988K
Financial strength
Current ratio
2.274
Quick ratio
1.717
Long term debt to equity
-779.943
Total debt to equity
-830.506
Interest coverage (TTM)
-1.95%
Profitability
EBITDA (TTM)
-33.65
Gross margin (TTM)
67.18%
Net profit margin (TTM)
-22.31%
Operating margin (TTM)
-14.73%
Effective tax rate (TTM)
-1.14%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
-11.06%
Return on equity (TTM)
-18,729.61%
Valuation
Price to revenue (TTM)
1.655
Price to book
-25.02
Price to tangible book (TTM)
-5.23
Price to free cash flow (TTM)
-9.145
Free cash flow yield (TTM)
-10.93%
Free cash flow per share (TTM)
-0.789
Growth
Revenue change (TTM)
17.15%
Earnings per share change (TTM)
7.82%
3-year revenue growth (CAGR)
28.04%
3-year earnings per share growth (CAGR)
-11.67%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Bulls say / Bears say
The successful US launch of Evolysse™ brought in $9.7 million in Q2 2025, marking the company’s best filler launch quarter in over ten years and broadening Evolus’s revenue sources beyond Jeuveau.
Jeuveau held a 14% share of the US neurotoxin market in the first half of 2025, supported by a 70% reorder rate and an increase of the Evolus Rewards program to more than 1.2 million members.
Evolus bolstered its financial position by arranging a $250 million term loan, of which $150 million has already been received, to drive commercial expansion and upcoming Evolysse™ international launches.
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $467M as of October 28, 2025.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of October 28, 2025.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.